Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chubb
Fuji
Deloitte
Harvard Business School
Baxter
Cantor Fitzgerald
Teva
Dow

Generated: April 25, 2018

DrugPatentWatch Database Preview

XALATAN Drug Profile

« Back to Dashboard

When do Xalatan patents expire, and what generic alternatives are available?

Xalatan is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in XALATAN is latanoprost. There are nineteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.
Drug patent expirations by year for XALATAN
Pharmacology for XALATAN
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Synonyms for XALATAN
(15R)-Latanoprost
(1R,2R,3R,5S,3''R)-7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic acid isopropyl ester
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptanoic acid 1-methylethyl ester
(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic Acid 1-Methylethyl Ester
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid propan-2-yl ester
(Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
130209-82-4
155551-81-8
209L824
33537-EP2295409A1
33537-EP2311820A1
5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester
5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-
6Z5B6HVF6O
A806039
AB00640005-04
AB00640005-06
AB2000019
ABP001061
AC1NSK8Q
AKOS024458331
Ambap130209-82-4
AR-202
AT-3016
BDBM50240648
C26H40O5
Catioprost
CCG-100946
CHEBI:6384
CHEMBL1051
CPD000466354
CS-2758
D00356
D0C6NM
DB00654
DTXSID1041057
GAAP Ofteno
GGXICVAJURFBLW-CEYXHVGTSA-N
GTPL1961
HMS2051H11
HMS2089J17
HY-B0577
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
Isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
Isopropyl-(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate
J-005764
Jsp001835
L-PPDS
L0262
L1167_SIGMA
latanoprost
latanoprost (isopropyl ester)
Latanoprost (JAN/USAN/INN)
Latanoprost [USAN:INN:BAN]
latanoprost free acid
Latanoprost, (+/-)-
Latanoprost, >=98% (HPLC), oil
Latanoprost, United States Pharmacopeia (USP) Reference Standard
latanoprostum
MFCD00216074
MLS000759468
MLS001424106
MolPort-003-942-862
NC00196
NCGC00246969-01
Nova-21027
PhXA 41
PHXA-41
PhXA34 [as 15(R,S)-isomer]
PhXA41
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-bis(oxidanyl)-2-[(3R)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
s4709
SAM001246671
SC-18987
SCHEMBL24698
SMR000466354
ST24047444
T-2345
TL8000716
Tris(2,4-dimethylphenyl)phosphine-5,5',5""""-trisulfonic acid trisodium salt
UNII-6Z5B6HVF6O
UNII-8S5FB3XXG8 component GGXICVAJURFBLW-CEYXHVGTSA-N
XA 41
XA-41
XA41
Xalatan (TN)
ZINC12468792

US Patents and Regulatory Information for XALATAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for XALATAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Mallinckrodt
Covington
Medtronic
Farmers Insurance
Argus Health
Teva
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.